SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the quarter ended March 31, 2009. Total revenue for the quarter ended March 31, 2009, was $369,000, compared with $653,000 for the same period in 2008. Total operating expenses for the quarter ended March 31, 2009, were $3.9 million, compared with $4.0 million for the same period in 2008. The net loss attributable to common stockholders for the quarter ended March 31, 2009, was $3.5 million, or $0.08 per share, compared with a net loss attributable to common stockholders of $3.0 million, or $0.07 per share for the same period in 2008.
